Balcinrenone, a selective MR modulator, was studied alongside dapagliflozin to assess their combined effects on UACR changes compared with dapagliflozin alone over 12 weeks in patients with symptomatic HF and LVEF <60% and CKD. This evidence concerns the gene NR3C2 and hydrops fetalis.